It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hydroxycarboxylic acid receptor 2 (HCAR2) belongs to the family of class A G protein-coupled receptors with key roles in regulating lipolysis and free fatty acid formation in humans. It is deeply involved in many pathophysiological processes and serves as an attractive target for the treatment of cardiovascular, neoplastic, autoimmune, neurodegenerative, inflammatory, and metabolic diseases. Here, we report four cryo-EM structures of human HCAR2–Gi1 complexes with or without agonists, including the drugs niacin (2.69 Å) and acipimox (3.23 Å), the highly subtype-specific agonist MK-6892 (3.25 Å), and apo form (3.28 Å). Combined with molecular dynamics simulation and functional analysis, we have revealed the recognition mechanism of HCAR2 for different agonists and summarized the general pharmacophore features of HCAR2 agonists, which are based on three key residues R1113.36, S17945.52, and Y2847.43. Notably, the MK-6892–HCAR2 structure shows an extended binding pocket relative to other agonist-bound HCAR2 complexes. In addition, the key residues that determine the ligand selectivity between the HCAR2 and HCAR3 are also illuminated. Our findings provide structural insights into the ligand recognition, selectivity, activation, and G protein coupling mechanism of HCAR2, which shed light on the design of new HCAR2-targeting drugs for greater efficacy, higher selectivity, and fewer or no side effects.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 The Chinese University of Hong Kong, Kobilka Institute of Innovative Drug Discovery, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Shenzhen, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482); The Affiliated Hospital of Yangzhou University, Yangzhou University, Department of Cardiology, Central Laboratory, Yangzhou, China (GRID:grid.268415.c)
2 The Chinese University of Hong Kong, Kobilka Institute of Innovative Drug Discovery, Shenzhen Futian Biomedical Innovation R&D Center, School of Medicine, Shenzhen, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482)
3 The Chinese University of Hong Kong, Warshel Institute for Computational Biology, School of Medicine, Shenzhen, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482)
4 Shenzhen University, Instrumental Analysis Center, Shenzhen, China (GRID:grid.263488.3) (ISNI:0000 0001 0472 9649)
5 The Chinese University of Hong Kong, Department of Chemistry, Shatin, Hong Kong SAR, China (GRID:grid.10784.3a) (ISNI:0000 0004 1937 0482)
6 The Affiliated Hospital of Yangzhou University, Yangzhou University, Department of Cardiology, Central Laboratory, Yangzhou, China (GRID:grid.268415.c)